Objective To evaluate whether single-dose treatments are as effective as standard therapy in the syndromic management of vaginal discharge. Methods A randomized controlled effectiveness trial compared single-dose tinidazole plus fluconazole (TF) with treatment for 7 days with metronidazole plus 3 days of treatment with vaginal clotrimazole (MC) among 1570 women presenting with vaginal discharge at primary health care institutions in Ghana, Guinea, Mali and Togo. Participants were randomly allocated to one of the two treatments by research nurses or physicians using precoded envelopes. Effectiveness was assessed by symptomatic response on day 14. Clinical identifier ClinicalTrials.gov NCT00313131. Findings The two treatment regimens had similar effectiveness: complete resolution was seen in 66% (TF) and 64% (MC) and partial resolution in 33% (TF) and 34% (MC) of participants (P = 0.26). Effectiveness was similar among subgroups with vulvovaginal candidiasis, Trichomonas vaginalis vaginitis or bacterial vaginosis. The two treatment regimens had a similar effectiveness among human immunodeficiency virus (HIV)-infected (TF: n = 76, 71% complete resolution, 28% partial; MC: n = 83, 72% complete resolution, 25% partial, P = 0.76) and HIV-uninfected women (TF: n = 517, 68% complete, 32% partial; MC: n = 466, 65% complete, 33% partial, P = 0.20). Cervical infections with Neisseria gonorrhoeae, Chlamydia trachomatis and Mycoplasma genitalium were uncommon among women not involved in sex work, were associated with bacterial vaginosis or T. vaginalis vaginitis, and did not alter response to treatment with agents active against vaginal infections. Four-fifths of women not relieved by a single dose of TF had a favourable response when MC was administered as second-line treatment. Conclusion Single-dose TF is as effective as multiple-dose MC in the syndromic management of vaginal discharge, even among women with HIV-infection. Given its low price and easier adherence, TF should be considered as a first-line treatment for vaginal discharge syndrome. Voir page 736 le résumé en français. En la página 736 figura un resumen en español.
Introduction
Despite the contradictory results of large trials in East Africa, the syndromic management of sexually transmitted infections (STI) remains a public health priority: whether or not it reduces transm m mission of human immunodeficiency virus (HIV), this intervention relieves patients' symptoms, lowers the risk of complications and reduces transmission of etiological agents. [1] [2] [3] [4] [5] Within core groups such as sex workers (SW) and their clients, STI could be important cofactors of HIV transmission even if this is less marked in the general adult population. 6 Furthermore, effective management of STI among SW can enhance the credibility and acceptability of interventions aimed primarily at inm m creasing the use of condoms. Syndromic management implies the simultaneous treatment of two or more infections: the higher cost of drugs is more than compensated by savings on diagnostic assays, but adverse effects are more frequent and adherence to mulm m tiplemdose regimens can be suboptimal. 1, 2 Whereas strategies for the syndromic management of STI in men are stanm m dardized and very effective, this is not yet the case for vaginal discharge, which is by far the most common STI syndrome among women. 1, 2 In the majority of cases, this syndrome is caused by either bacterial vaginosis (BV), Trichomonas vaginalis (TV) vaginitis, vulvovaginal candidiasis (CA) or any combination thereof. In West Africa, classical agents of cervicitis (Neisseria gonorrhoeae (NG) or Chlamydia trachomatis (CT)) are found in only 5-10% of women who are not SW and 10-25% of SW seeking treatm m ment for a vaginal discharge. [7] [8] [9] [10] [11] To these pathogens must be added Mycoplasma genitalium, recently identified as an agent of cervicitis in West Africa. 10 The emerm m gence of a generic drug industry in the developing world has led to a significant reduction in the cost of STI syndromic management, even with singlemdose drugs. [12] [13] [14] To determine whether singlem dose therapy would be as effective as standard therapy in the context of African primary health care institutions providing care to populations with a relatively high prevalence of HIV, we Women not eligible for the study were treated acm m cording to the algorithms routinely used in the health facility. At the initial visit, a questionnaire was used to gather information on dem m mographic and behavioural characterism m tics, current complaints and the recent intake of antimicrobials. During gynaem m cological examination, the presence of vulvar inflammation, the characteristics of the discharge and signs of cervicitis (mucopurulent cervical discharge, pus on the swab, cervical bleeding after sampling and cervical inflammation) were noted. Two samples were obtained from secretions in the vaginal fornix and two from the endocervix, after cleaning the latter. The first vaginal sample was deposited in the Amplicor transport medium (Roche, USA) and used for the detection of Trichomonas vaginalis; the second was used to deposit secretions on a slide which was Grammstained to detect the presence of BV (Nugent score >7) 15 and/or yeasts compatible with Candida albicans. The first cervical sample, dem m posited in the Amplicor medium, was tested by polymerasemchain reaction (PCR) for the presence of NG, CT and Mycoplasma genitalium (MG); 7,10 the second was used to measure the leukom m cyte count per highmpower field (hpf ) as the mean of five counts. HIV serology was performed on capillary blood using an algorithm of two different enzyme immunoassays (DetectmHIV, Adaltis, Canada and Genie II HIVm1/HIVm2, BiomRad, France) and INNOmLIA HIV I/II Score (Innogenetics, Belgium) was used for the confirmation of discordant results between the first and second enzyme immunoassays.
Participants were identified only by a study number. Laboratory assays, inm m cluding HIV serology, were performed anonymously. Women wishing to know their HIV status received premtest counm m selling and a properly identified sample of venous blood was obtained. Processm m ing of this sample, postmtest counselling, and eventual referral to a facility providm m ing treatment with antiretrovirals were performed as routinely done for patients not participating in the study.
Randomization
Randomization, stratified according to whether or not the woman was a sex worker, was conducted in each particim m pating centre by the research nurses or physicians, using premcoded envelopes. Participants were randomly assigned to a group receiving either tinidazole 2 g, single dose and fluconazole 150 mg, single dose or metronidazole 500 mg twice a day for 7 days and clotrimazole vaginal cream for 3 days. Women found to have at least one sign of cervicitis were given ciprofloxacin (500 mg, single dose) and azithromycin (1 g, single dose); those with a genital ulcer received ciprofloxacin (500 mg twice a day for 3 days) and benzathine penicillin (2.4 M units intramuscular, single dose). Fluconazole, tinidazole and, when necm m essary, ciprofloxacin and azithromycin, were swallowed by the patient under direct observation. Patients allocated to the group receiving metronidazole and clotrimazole used these drugs at home. Because the study aimed to measure effectiveness, generic drugs bought in West Africa were used. It would have been impractical to use placebos. Given the low prevalence of gonococcal and chlamydial infections anticipated among nonmSW, 10 no attempt was made to treat their male partners.
Follow-up and outcomes
Participants were asked to come for a followmup visit on day 14. A questionm m naire verified the subjective response to treatment, which was the primary outcome. A clinical examination was performed to document whether there was an objective resolution of the vaginal discharge (secondary outcome). Vaginal and cervical samples were obtained for Gram staining: other secondary outcomes were the disappearance of C. albicans and the resolution of BV in vaginal secretions. Participants still complaining of vaginal discharge were given oral metronidazole (500 mg twice a day for 7 days) and clotrimazole cream (for 3 days) and asked to come back on day 28. If this second treatment led to no improvement, the choice of therapy was then left to the discretion of local healthmcare workers.
Sample size and statistical analyses
Aiming for 90% power, an alpha of 0.05, assuming that 50% of particim m pants would have BV, that 25% of all women would be lost to followmup and that the effectiveness of a 7mday course of metronidazole in women with BV would be 90%, we needed 381 women with BV in each group to show that the difference in effectiveness between metronidazole and tinidazole would be inferior to 10%. We aimed to enrol 1524 participants. Data were analysed with Stata 8.0 software. Categorical variables were compared using the c² or Fisher's test. Logistic regression was used for multivariate analysis.
Clinical identifier
ClinicalTrials.gov NCT00313131.
Results
A total of 811 women were randomly assigned to receive tinidazole/fluconm m azole, and 759 to receive metronidazole/ clotrimazole (Table 1 and Trial profile ( Fig. 1) ), suggesting that the randomizam m tion procedure was not always respected. Nevertheless, the groups were well balm m anced and no significant difference was seen between them in age, sex work, duration of discharge, prior treatment, presence of other symptoms, signs of
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Single-dose treatment of vaginal discharge 10,16 we first tested for this association with cervicitis, initially defining cervicitis as a leukocyte count on cervical secretions >10/hpf. In a logistic regression analysis that adjusted for age and the presence of other pathogens, presence of MG was associated with cervicitis (adjusted odds ratio (AOR): 2.0, 95% confidence interval (CI): 1.3-3.2, P = 0.004) as was NG (AOR: 2.2, 95% CI: 1.3-3.6, P = 0.003) and CT (AOR: 1.7, 95% CI: 1.0-3.0, P = 0.05). Subsequent analyses thus considered women in whom any of these three pathogens was present, alone or in combination, as having cervical inm m fections. Interestingly, if we used a higher (>30 leukocytes/hpf ) cutmoff point to define cervicitis, NG (AOR: 2.4, 95% CI: 1.3-4.6, P = 0.007) and MG (AOR: 2.0, 95% CI: 1.1-3.7, P = 0.02) remained associated with cervicitis but not CT (AOR: 1.2, 95% CI: 0.5-2.7, P = 0.66). Women among whom at least one agent of cervicitis was found were more likely to also have BV and TV vaginitis than those without cervical infections ( Table 2) .
Fourmfifths of participants attended the followmup visit on day 14 (metrom m nidazole/clotrimazole: 591/759, 78%; tinidazole/fluconazole: 653/811, 81%) (Trial profile (Fig. 1) ). The proportion of women who reported either a complete resolution of the discharge or partial improvement on day 14 was similar in the two treatment groups (Table 3) . Both treatments had similar effectiveness when analysis was restricted to subgroups: women with BV, those with candidiasis, those with trichomoniasis and women with cervical infections (NG, CT and/or MG). The two treatments had the same overall effectiveness among HIVminfected participants as among those who were seronegative. The presence of a visible vaginal discharge on day 14 was highly correlated with the patient's own perm m ception of response to treatment: 93% (14/15) of women reporting no improvem m ment had a visible discharge on day 14 as did 86% (358/418) of those reporting partial improvement, compared to 15% (116/759) of those reporting complete resolution (P <0.001). There was no difm m ference between treatment groups for the presence of a vaginal discharge on examination on day 14, neither overall nor when examining the subgroups dem m scribed above (data not shown).
Among women with vaginitis, we examined the presence of abnormal findm m ings on day 14 and their relation with subjective or objective improvement of the discharge. Among women with BV on enrolment who were seen on day 14, 165/542 (30%) still had a Nugent score of 7 or more, but this was as frequent in those with complete resolution of dism m charge (90/319, 28%) as in those with only partial or no improvement (72/215, 33%) (P = 0.23), as well as among those with (75/240, 31%) or without a visible discharge (86/293, 29%) (P = 0.70). However, among women with candim m diasis on enrolment, yeasts were more frequently found on day 14 among those with partial or no improvement of symptoms (81/166, 49%) than those with complete resolution (48/193, 25%) (P <0.001), and were also more common among those with a visible discharge Research Jacques Pépin et al.
Single-dose treatment of vaginal discharge (88/189, 47%) than those without any discharge (40/169, 24%) (P<0.001).
Taking as a secondary outcome the presm m ence of yeasts on day 14, there was no difference between treatment groups among the HIV seronegatives or among those with HIV infection (data not shown).
Of 433 women without complete resolution on day 14 who were then treated with metronidazole/clotrimazole, 358 (83%) attended a further followmup visit on day 28: more than 80% of these women reported a complete resolution of the discharge on day 28, regardless of the treatment received on day 0 and regardless of the presence of objective evidence of vaginosis or candidiasis on day 14 (Table 4) .
Finally, we examined whether the presence of signs of cervicitis on exm m amination was correlated with cervical infections (Table 5 ). Signs of cervicitis were not associated with the presence of NG, CT and/or MG. However, among SW the presence of NG, CT and/or MG was correlated with the leukocyte count in cervical secretions, a higher prevalence being seen as soon as the leukocyte count was >3/hpf. The presence of spermatozoa on Gram stains of vaginal secretions was correlated with the presence of NG, CT and/or MG. We examined the perform m mance of determining the indication for providing treatment for cervical infections based on the presence of a leukocyte count >4/hpf. Among SW this approach had a sensitivity of 64% (79/123) and a positive predictive value of 30% (79/264). Among nonmSW the sensitivity was 53% (28/53) and the posim m tive predictive value only 7% (28/413).
Discussion
A combination of singlemdose tinidam m zole/fluconazole was as effective as the longer standard course of metronidazole (7 days)/clotrimazole (3 days) in women presenting with vaginal discharge to prim m mary health care facilities in four West African countries. The effectiveness of the two treatments was similar when examining all women, but also among subgroups selected according to the presm m ence of various etiological agents. Imporm m tantly, the two treatments were equally effective in HIVminfected women.
Bacterial vaginosis was the most common etiology of vaginal discharge, both among SW and nonmSW, in line with previous studies. 17, 18 We defined BV using the Nugent score which, compared to the Amsel criteria, is simpler, more reproducible, and has reasonable sensim m tivity and specificity. 15, [19] [20] [21] The standard treatment of BV is a 7mday course of metronidazole; singlemdose metronidam m zole is slightly less effective. 2, [20] [21] [22] [23] The effectiveness of singlemdose metronidam m zole in women with BV is lower among those who are seropositive for HIV than in those who are seronegative. 18 BV, an infection characterized by frequent relapses after initial improvement, has been the limiting step in the overall management of vaginal discharge with singlemdose therapies. Given its longer halfmlife (12-14 hours versus 6-7 hours for metronidazole), 24 tinidazole would be expected to be more effective as a singlemdose therapy. It is better tolerated than metronidazole 25, 26 and very cheap (wholesale price per 2 g dose ≈ US$ 0.07). Studies of singlemdose tinidazole in women with BV have shown a wide range of effectiveness (51-97%) [27] [28] [29] [30] but used different definitions of BV and cure. Experts now agree that the goal of BV treatment is symptomatic relief. 20 In this regard, singlemdose tinidazole was equivalent to a week of treatment with metronidazole, even among HIVm infected women.
The prevalence of TV among sympm m tomatic participants in the present study was low, mirroring the results of popum m lational surveys of asymptomatic women which documented a prevalence of only 3% in Cotonou (Benin), compared to 18-34% in Yaoundé (Cameroon), Kisumu (Kenya) and Ndola (Zambia). 31 To treat T. vaginalis infections, WHO and others recommend as first choice, singlemdose metronidazole (2 g), 2, 22, 23 which has an effectiveness comparable to that of a 5-7 day course of the same drug. 25, 26 Tinidazole was compared to metronidazole in early randomized trials; 32,33 a metamanalysis of these sugm m gested that singlemdose tinidazole was superior to singlemdose metronidazole. 25 We showed that singlemdose tinidazole was as effective against TV as 7 days of metronidazole.
Previously, in submSaharan Africa, the treatment of vaginal candidiasis relied on nystatin, with unsatisfactory results. Nystatin was replaced with azolem containing creams, with better results. A generic clotrimazole pessary remains little used. Singlemdose oral fluconazole offers an interesting alternative, as it can be combined with singlemdose tinidazole and given under direct observation. 34 Generic fluconazole is now cheaper (US$ 0.13 for 150 mg) than the clotrimazole pessary (US$ 0.84). [12] [13] [14] Whether vulvom m vaginal candidiasis is more common or more likely to recur among HIVminfected women is controversial, and there was little information on the effectiveness of singlemdose fluconazole in HIVminfected women. 35 We found no difference in effectiveness between fluconazole and clotrimazole in HIVminfected particim m pants, and no difference in response bem m tween HIVminfected and HIVmnegative women with candidiasis.
Signs of cervicitis on examination were not reliable predictors of cervical infections. Of 560 nonmSW women with >1 sign of cervicitis given ciprofloxacin/ azithromyin, only 30 (5.4%) had a cervim m cal infection. Most women with cervical infection also had vaginitis, which most likely prompted their consultation; indeed, presumably because of their association with sexual activity, BV and TV were more common among women with cervical infections. Only 53 (5.4%) of nonmSW were infected with NG, CT and/or MG; of these only 18 and 28 had >10 and > 4 leukocytes/hpf, respecm m tively. In light of these low prevalences, attempting to identify nonmSW with cervical infections seems pointless. Control of NG, CT and MG in the general population of African countries requires these infections to be controlled among SW: decreasing transmission to their clients will ultimately reduce inm m fections among women not involved in transactional sex. Effective singlemdose treatments for gonorrhoea and chlamydia are available, although the emergence of ciprofloxacinmresistant gonococci in South Africa is a matter for concern. 36 There are two possible approaches for managing cervical infections among SW. Early in an intervention, when condom use is low and prevalences of cervical infections are high, administering drugs active against agents of cervicitis to all SW will have a sensitivity of 100% and a positive predictive value equal to the prevalence. Later on, when prevalence of cervical infections decreases, the ecom m logical disadvantages (selective pressure for resistance) become a consideration: treatment active against agents of cervical infections might then be given only to SW with >4 leukocytes/hpf in cervical 10, 16 The development of cheap dipsticks that would detect the presence of leukocytes might be more easily attainable.
Crossmsectional and cohort studies have examined the association between HIV and vaginitis. [37] [38] [39] [40] [41] [42] A metamanalysis estimated that the risk of acquiring HIV was increased 1.4-2.2mfold by BV, TV and candidiasis. 40 Although there is no evidence that adequate treatment of BV reduces the risk of HIV, the high prevalence of BV suggests that its population attributable fraction of incident HIV among women could be substantial. 37 HIV vaginal shedding is higher in women with candidiasis, and is reduced by treatment of candidiasis and TV. 43, 44 Conclusions Among nonmSW at low risk for HIV, the goal is symptomatic relief and singlem dose tinidazole/fluconazole could be used as the initial treatment for vaginal discharge, because it is convenient, well tolerated and cheap (wholesale price: US$ 0.20). Most women who do not respond to tinidazole/fluconazole are cured when given as secondmline 
Resumen
Manejo sindrómico del flujo vaginal mediante tratamientos de dosis única: ensayo controlado aleatorizado en África Occidental
Objetivo Determinar si los tratamientos de dosis única son eficaces como terapia estándar en el manejo sindrómico del flujo vaginal. Métodos En un ensayo controlado aleatorizado se comparó la eficacia de una dosis única de tinidazol y fluconazol (TF) con la de un tratamiento con metronidazol durante 7 días seguido de clotrimazol vaginal durante 3 días más (MC) en un total de 1570 mujeres que acudieron con problemas de flujo vaginal a establecimientos de atención primaria de Ghana, Guinea, Malí y Togo. Utilizando sobres precodificados, enfermeras y médicos investigadores asignaron aleatoriamente a las participantes a alguno de los dos tratamientos. La eficacia se evaluó determinando la respuesta sintomática a los 14 días. Identificador clínico ClinicalTrials.gov NCT00313131.
Resultados Los dos regímenes terapéuticos tuvieron una eficacia parecida: curación completa en el 66% (TF) y el 64% (MC) de los casos, y curación parcial en el 33% (TF) y el 34% (MC) de los casos (P = 0,26). La eficacia fue similar entre los subgrupos con candidiasis vulvovaginal, vaginitis por Trichomonas vaginalis o vaginosis bacteriana. Los dos regímenes terapéuticos tuvieron también parecida eficacia en las pacientes infectadas por el virus de la inmunodeficiencia humana (VIH) (TF: n = 76, curación completa en el 71% de los casos, y parcial en el 28% de los casos; MC: n = 83, curación completa en el 72% de los casos, y parcial en el 25%; P = 0,76) y las no infectadas por el VIH (TF: n = 517, curación completa en el 68% de los casos, y parcial en el 32%; MC: n = 466, curación completa en el 65% de los casos, y parcial en el 33%; P = 0,20). Las infecciones cervicouterinas por Neisseria gonorrhoeae, Chlamydia trachomatis y Mycoplasma genitalium eran infrecuentes entre las mujeres que no eran profesionales del sexo, se asociaban a vaginosis bacteriana o vaginitis por T. vaginalis, y no influían en la respuesta al tratamiento con productos activos contra las treatment a standard course of metrom m nidazole/clotrimazole (wholesale price: US$ 1.06). Among SW, in addition to symptomatic relief, this visit to a health worker should be used as an opportum m nity for promotion of condom use and screening for cervical infections. O
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